FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Group Seeks Stronger Pregnancy Warning on Antidepressants

[ Price : $8.95]

Advocacy group Public Citizen petitions FDA to add new, class-wide pregnancy warnings to the labels of commonly prescribed seroton...

FDA Flags AstraZenecas Farxiga TV Ad as Misleading

[ Price : $8.95]

FDA cites a direct-to-consumer television advertisement for AstraZenecas Farxiga (dapagliflozin) tablets.

Hims & Hers Names Ex-FDAer Autor as Chief Policy Officer

[ Price : $8.95]

Hims & Hers Health appoints former FDA Global Regulatory Operations and Policy deputy commissioner Deb Autor as its first chief po...

NIH Grant Cuts Disrupt Hundreds of Clinical Trials: JAMA

[ Price : $8.95]

A new JAMA research letter finds that more than 380 clinical trials supported by the NIH lost funding this year affecting about 1...

RFK Jr. reportedly Mulled Limiting Makarys Authority

[ Price : $8.95]

HHS secretary Robert F. Kennedy Jr. reviews options to scale back the operational role of FDA commissioner Marty Makary, including...

Promising Ziihera Data in Gastric Cancer Trial

[ Price : $8.95]

Zymeworks reports that its HER2-targeted bispecific antibody Ziihera (zanidatamab-hrii) significantly improved outcomes for patien...

BMS, J&J Halt Phase 3 Librexia Trial After Futility Review

[ Price : $8.95]

Bristol Myers Squibb (BMS) and Johnson & Johnson stop their Phase 3 Librexia ACS trial of the investigational anticoagulant milvex...

FDA Previews Reforms as Pazdur Takes Over CDER

[ Price : $8.95]

FDA commissioner Marty Makary and CBER director Vinay Prasad preview upcoming agency reforms during an FDA Direct podcast focused ...

Rising Concerns Over FDA Consistency, Transparency: Axios

[ Price : $8.95]

An Axios report examines growing criticism of recent FDA actions that are fueling uncertainty among drug developers and weakening ...

ACLU Sues FDA for Records on Mifepristone Review

[ Price : $8.95]

The ACLU files a lawsuit seeking to force FDA to release documents related to its ongoing safety review of mifepristone.